D&D PHARMATECH INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29,100 KRW | -2.68% |
|
-19.39% | 0.00% |
| Sales 2022 | 611M 448K | Sales 2023 | 18.68B 13.71M | Capitalization | 314B 231M |
|---|---|---|---|---|---|
| Net income 2022 | -136B -99.87M | Net income 2023 | 3.93B 2.89M | EV / Sales 2022 * | - |
| Net cash position 2022 * | - 0 | Net cash position 2023 * | - 0 | EV / Sales 2023 * | - |
| P/E ratio 2022 * |
-
| P/E ratio 2023 * |
-
| Employees | - |
| Yield 2022 * |
-
| Yield 2023 * |
-
| Free-Float | 99.43% |
More Fundamentals
* Assessed data
| 1 day | -2.68% | ||
| 1 week | -19.39% |
1 week
28 800.00
32 100.00
1 month
28 800.0053 900.00
Current year
28 800.0053 900.00
1 year
28 800.0053 900.00
3 years
28 800.0053 900.00
5 years
28 800.0053 900.00
10 years
28 800.0053 900.00
DND Pharmatech Inc is a Korea-based clinical-stage biotech company mainly engaged in the research and development in medicines. The Company's product pipeline mainly focuses on indications including metabolic disease, neurodegenerative and fibrotic diseases. In addition, the Company is engaged in the research and development of therapeutic medicines used for diabetes, obesity and nonalcoholic steatohepatitis as well as others.
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 231M | |
| +9.83% | 118B | |
| +10.80% | 106B | |
| -10.84% | 23.4B | |
| -1.69% | 22.1B | |
| -10.23% | 18.34B | |
| -41.92% | 16.59B | |
| -15.11% | 15.97B | |
| +6.62% | 14.03B | |
| +17.53% | 11.67B |
- Stock Market
- Equities
- A347850 Stock
